Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Takeda
Fusion Pharmaceuticals Inc.
Tempus AI
Actym Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Bolt Biotherapeutics, Inc.
Elevation Oncology
Turnstone Biologics, Corp.
Aminex Therapeutics, Inc.
NantCell, Inc.
Ikena Oncology
Eisai Inc.
CytomX Therapeutics
Atreca, Inc.
Fusion Pharmaceuticals Inc.
Fate Therapeutics
Hoffmann-La Roche
Oncorus, Inc.
MacroGenics
Seagen Inc.
AIDS Malignancy Consortium
National Institutes of Health Clinical Center (CC)
Dartmouth-Hitchcock Medical Center
Seagen Inc.
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
sigma-tau i.f.r. S.p.A.
University of Pittsburgh
University Health Network, Toronto
Icahn School of Medicine at Mount Sinai
Masonic Cancer Center, University of Minnesota
Stanford University
Otsuka Novel Products GmbH
Sir Mortimer B. Davis - Jewish General Hospital
Calando Pharmaceuticals
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center